Patients with a previous histologic diagnosis of prostate cancer with a rising prostate-specific antigen (PSA) level and/or tumor progression on radiologic studies (including bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI)), despite androgen deprivation therapy (ADT) and castrate testosterone levels were eligible for the study. Here, KLK3 is linked to prostate cancer.